Granted Patent
B2
US 12,569,556 · App. 17/161,772 · Granted Mar 10, 2026
Aluminum based adjuvants for tolerogenic vaccination
Assignee:
East Carolina University
A61K39/39A61K9/0019A61K33/06A61K38/19A61K38/215A61K39/0008A61K47/02A61P37/06A61K2039/55505A61K2039/55511A61K2039/55522A61K2039/577A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides methods of modulating an immunological disorder or an immune response. The methods include administering to a subject or a cell an effective amount of an autoimmune antigen and an anti-inflammatory cytokine included in an aluminum-based carrier. Compositions including an autoimmune antigen and an anti-inflammatory cytokine included in an aluminum-based carrier are also provided.
Claims (22)
1 . A composition comprising:
(a) an autoimmune antigen selected from the group consisting of proteolipid protein (PLP), myelin oligodendrocyte glycoprotein (MOG), myelin-associated oligodendrocytic basic protein and cardiac myosin, or portions thereof, wherein the portions comprise the encephalitogenic determinant portion;
(b) an anti-inflammatory cytokine that is interferon alpha or interferon beta; and
(c) an aluminum-based adjuvant which is noncovalently bound to both the autoimmune antigen and the anti-inflammatory cytokine,
wherein the autoimmune antigen and the interferon alpha or interferon beta are not covalently linked.
2 . The composition of claim 1 , wherein the autoimmune antigen is an encephalitogenic determinant portion of an autoimmune antigen selected from the group consisting of proteolipid protein (PLP), myelin oligodendrocyte glycoprotein (MOG), myelin-associated oligodendrocytic basic protein and cardiac myosin, or portions thereof.
3 . The composition of claim 1 , wherein the anti-inflammatory cytokine is IFN-β.
4 . The composition of claim 1 , wherein the anti-inflammatory cytokine is IFN-α.
5 . The composition of claim 1 , wherein the aluminum-based adjuvant comprises aluminum hydroxide.
6 . The composition of claim 1 , wherein the aluminum-based adjuvant comprises aluminum oxyhydroxide.
7 . The composition of claim 1 , wherein the aluminum-based adjuvant comprises aluminum hydroxyphosphate.
8 . The composition of claim 1 , wherein the autoimmune antigen is proteolipid protein (PLP) or a portion thereof.
9 . The composition of claim 1 , wherein the autoimmune antigen is myelin oligodendrocyte glycoprotein (MOG) or a portion thereof.
10 . The composition of claim 1 , wherein the autoimmune antigen is myelin-associated oligodendrocytic basic protein and cardiac myosin or a portion thereof.
11 . The composition of claim 2 , wherein the encephalitogenic determinant portion of the PLP, MOG, myelin-associated oligodendrocytic basic protein or cardiac myosin is an amino acid sequence encoded by a nucleic acid sequence encoding an encephalitogenic determinant portion of the PLP, MOG, myelin-associated oligodendrocytic basic protein or cardiac myosin.
12 . The composition of claim 2 , wherein the encephalitogenic determinant portion of the PLP, MOG, myelin-associated oligodendrocytic basic protein or cardiac myosin is an amino acid sequence encoded by a nucleic acid sequence that hybridizes, under stringent conditions as represented by hybridization conditions of 0.5M NaHP0 4 , 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65° C. and wash conditions of 0.1×SSC/0.1% SDS at 68° C., with the complement of an amino acid sequence encoded by a nucleic acid sequence encoding an encephalitogenic determinant portion of the PLP, MOG, myelin-associated oligodendrocytic basic protein or cardiac myosin.
13 . A kit comprising one or more container(s) including a pharmaceutical dosage unit comprising an effective amount of the composition of claim 1 , wherein the kit is packaged with optional instructions for the use of the composition.
14 . A composition comprising:
(a) myelin oligodendrocyte glycoprotein (MOG),
(b) interferon beta; and
(c) an aluminum-based adjuvant which is bound to both the autoimmune antigen and the anti-inflammatory cytokine,
wherein the MOG and the interferon beta are not covalently linked.
Assignments (1)
CONFIRMATORY LICENSE
Recorded Nov 2, 2023
From: EAST CAROLINA UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065431/0149 →
Continuity (3)
Division
15763739
Provisional Application
62233608
· Sep 28, 2015
References Cited (197)
US 4501729A
· Boucher et al.
· 1985
[cited by applicant]
US 4701416A
· Nunberg
· 1987
[cited by applicant]
US 5151264A
· Samain et al.
· 1992
[cited by applicant]
US 5288931A
· Chang
· 1994
[cited by examiner]
US 5496924A
· Habermann et al.
· 1996
[cited by applicant]
US 5521288A
· Linsley et al.
· 1996
[cited by applicant]
US 5837816A
· Ciardelli et al.
· 1998
[cited by applicant]
US 5981221A
· Hillman et al.
· 1999
[cited by applicant]
US 5994104A
· Anderson et al.
· 1999
[cited by applicant]
US 6109885A
· Micklisch et al.
· 2000
[cited by applicant]
US 6211342B1
· Hirsch et al.
· 2001
[cited by applicant]
US 6211427B1
· Cottingham et al.
· 2001
[cited by applicant]
US 6251396B1
· Gaur et al.
· 2001
[cited by applicant]
US 6369199B2
· Guegler et al.
· 2002
[cited by applicant]
US 6482409B1
· Lobb et al.
· 2002
[cited by applicant]
US 6555342B1
· Kappes et al.
· 2003
[cited by applicant]
US 6972322B2
· Fleer et al.
· 2005
[cited by applicant]
US 6987006B2
· Fleer et al.
· 2006
[cited by applicant]
US 7087411B2
· Daly et al.
· 2006
[cited by applicant]
US 7112659B2
· Mann et al.
· 2006
[cited by applicant]
US 7112660B1
· Domingues
· 2006
[cited by examiner]
US 9745361B2
· Mannie
· 2017
[cited by examiner]
US 20020076412A1
· Steinman
· 2002
[cited by examiner]
US 20080193440A1
· Jensen
· 2008
[cited by applicant]
US 20120082644A1
· Mannie
· 2012
[cited by examiner]
WO 9324640A2
· 1993
[cited by applicant]
WO 9427435A1
· 1994
[cited by applicant]
WO 2008130382A2
· 2008
[cited by applicant]
WO 2010056143A1
· 2010
[cited by applicant]
WO 2010117848A1
· 2010
[cited by applicant]
WO 2011014871A1
· 2011
[cited by applicant]
WO 2012178160A2
· 2012
[cited by applicant]
Hogenesch et al, (Frontiers in Immunology, 2013; vol. 3, article 406, pp. 1-13).
[cited by examiner]
Tokuriki et al., 2009, Curr. Opin. Struc. Biol. 19:596-604.
[cited by examiner]
Bhattacharya et al. (2017, PLoS One 12(3): e0171355, https://doi.org/10.1371/journal.pone.0171355).
[cited by examiner]
Alaoui-Ismaili (2009, Cytokine Growth Factor Rev. 20(5-6):501-507).
[cited by examiner]
Ulloa-Aguirre et al. (2004, Traffic 5:821-837).
[cited by examiner]
Bernier et al. (2004, Curr. Opin. Pharmacol. 4:528-533).
[cited by examiner]
Abbio Tec Product Datasheet for MBP [87-99] Peptide (Year: NA).
[cited by examiner]
Wallberg et al. European Journal of Immunology. 33: 1539-1547; Published: May 9, 2003 (Year: 2003).
[cited by examiner]
Hogenesch et al., (Frontiers in Immunology, 2013; vol. 3, article 406, pp. 1-13). (Year: 2013).
[cited by examiner]
Abbio Tec Product Datasheet for MBP [87-99] Peptide (Year: NA) (Year: na).
[cited by examiner]
Krewski et al. Journal of Toxicology and Environmental Health, Part B, Critical Reviews. 10(1): 1-269; Published: Nov. 25, 2009 (Year: 2009).
[cited by examiner]
Charlton et al. Current Opinion in Immunology. 7: 793-798; Published: Dec. 1995 (Year: 1995).
[cited by examiner]
Ludvigsson et al. New England Journal of Medicine. 359: 1909-1920: Published: Oct. 8, 2008 (Year: 2008).
[cited by examiner]
Wherrett et al. Lancet. 378: 319-327; Published: Jun. 27, 2011 (Year: 2011).
[cited by examiner]
Wållberg et al. European Journal of Immunology. 33: 1539-1547; Published: May 9, 2003 (Year: 2003).
[cited by examiner]
Fulgenzi et al. BioMed Research International. 2014: 758323; Published: Aug. 27, 2014 (Year: 2014).
[cited by examiner]
Guimarães et al. Pharmacological Research. 100: 190-209; Published: Aug. 12, 2015 (Year: 2015).
[cited by examiner]
Bagavant et al. Clinical Experimental Rheumatology. 32(2): 251-255; Published: Apr. 9, 2015 (Year: 2015).
[cited by examiner]
Ludvigsson et al. New England Journal of Medicine. 366(2): 433-442; Published: Feb. 2, 2012 (Year: 2012).
[cited by examiner]
Wigren et al. Circulation Research. 104: e62-e70; Published: May 28, 2009 (Year: 2009).
[cited by examiner]
Piconese et al. Cytokine & growth Factor Reviews. 26: 133-141; Published: Oct. 31, 2014 (Year: 2014).
[cited by examiner]
“Abreu, S. L. “Suppression of experimental allergic encephalomyelitis by interferon” Immunological Communications, 11(1):1-7 (1982) (Abstract only)”.
[cited by applicant]
“Brewer, J.M. “(How) do aluminium adjuvants work?” Immunology Letters, 102(1):10-15 (2005) (Abstract only)”.
[cited by applicant]
“Communication pursuant to Rule 164(1) EPC: partial supplementary European Search Report corresponding to European Patent Application No. 16852494.0 (15 pages) (dated Apr. 18, 2019)”.
[cited by applicant]
“Corthay, Alexandre “How do regulatory T cells work?” Scandinavian Journal of Immunology, 70:326-336 (2009)”.
[cited by applicant]
“Darlington, Cynthia “MBP-8298, a synthetic peptide analog of myelin basic protein for the treatment of multiple sclerosis” Current Opinion in Molecular Therapeutics, 9(4):398-402 (2007) (Abstract only)”.
[cited by applicant]
“Derwenskus, Joy “Current Disease-Modifying Treatment of Multiple Sclerosis” Mount Sinai Journal of Medicine, 78(2):161-175 (2011) (Abstract only)”.
[cited by applicant]
“European Patent Office Communication pursuant to Article 94(3) EPC corresponding to European Patent Application No. 16852494.0 (7 pages) (dated Apr. 7, 2020)”.
[cited by applicant]
“Extended European Search Report corresponding to European Patent Application No. 16852494.0 (12 pages) (dated Jul. 29, 2019)”.
[cited by applicant]
“Freedman, Mark S. “Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome” Therapeutic Advances in Neurological …
[cited by applicant]
“Garren, H. “A DNA vaccine for multiple sclerosis” Expert Opinion on Biological Therapy, 8(10):1539-1550 (2008) (Abstract only)”.
[cited by applicant]
“Garren, Hideki “DNA vaccines for autoimmune diseases” Expert Review of Vaccines, 8(9):1195-1203 (2009) (Abstract only)”.
[cited by applicant]
“Ghimire, Tirth Raj “The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm” SpringerPlus, 4(181):1-18 (2015)”.
[cited by applicant]
“Goodin, Douglas S. “The Use of Interferon Beta and Glatiramer Acetate in Multiple Sclerosis” Seminars in Neurology, 33(1):13-25 (2013) (Abstract only)”.
[cited by applicant]
“International Preliminary Report on Patentability corresponding to International Patent Application No. PCT/US2016/054192 (7 pages) (mailed Apr. 12, 2018)”.
[cited by applicant]
“Kieseier, Bernd C. “The Mechanism of Action of Interferon-beta in Relapsing Multiple Sclerosis” CNS Drugs, 25(6):491-502 (2011) (Abstract only)”.
[cited by applicant]
“Plosker, Greg L. “Interferon-beta-1b: a review of its use in multiple sclerosis” CNS Drugs, 25(1):67-88 (2011) (Abstract only)”.
[cited by applicant]
“Steinman, Lawrence “The gray aspects of white matter disease in multiple sclerosis” Proceedings of the National Academy of Sciences USA, 106(20):8083-8084 (2009)”.
[cited by applicant]
“Swanborg, Robert H. “Antigen-Induced Inhibition of Experimental Allergic Encephalomyelitis: II. Studies in Guinea Pigs with the Small Rat Myelin Basic Protein” The Journal of Immunology, 111(4):1067-1070 (1973)”.
[cited by applicant]
“Wan, Yisong Y. “GATA3: A master of many trades in immune regulation” Trends in Immunology, 35(6):233-242 (2014)”.
[cited by applicant]
“Wraith, David C. “Therapeutic peptide vaccines for treatment of autoimmune diseases” Immunology Letters, 122(2):134-136 (2009)”.
[cited by applicant]
Abbott , et al., “Neuroantigen-specific, tolerogenic vaccines: GM-CSF is a fusion partner that facilitates tolerance rather than immunity to dominant self-epitopes of myelin in murine models of experimental autoimmune e…
[cited by applicant]
Aimanianda , et al., ““Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants” Trends in Pharmacological Sciences, 30(6):287-295 (2009) (Abstract only)”.
[cited by applicant]
Aristimuno , et al., ““IFNbeta-1a therapy for multiple sclerosis expands regulatory CD8+ T cells and decreases memory CD8+ subset: A longitudinal 1-year study” Clinical Immunology, 134:148-157 (2010)”.
[cited by applicant]
Arnold , et al., ““A novel monoclonal antibody against rat LFA-1: blockade of LFA-1 and CD4 augments class II MHC expression on T cells” Hybridoma, 17(4):331-338 (1998) (Abstract only)”.
[cited by applicant]
Axtell , et al., ““T helper type 1 and 17 cells Determine Efficacy of interferon-beta in Multiple Sclerosis and Experimental Encephalomyelitis” Nature Medicine, 16(4):406-412 (2010)”.
[cited by applicant]
Axtell , et al., ““Type I Interferons: Beneficial in Th1 and Detrimental in Th17 Autoimmunity” Clinical Reviews in Allergy & Immunology, 44(2):114-120 (2013)”.
[cited by applicant]
Baine , et al., ““Helios induces epigenetic silencing of II2 gene expression in regulatory T cells” The Journal of Immunology, 190(3):1008-1016 (2013)”.
[cited by applicant]
Bielekova, et al., ““Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand” Nature Medicine, 6(10):…
[cited by applicant]
Bin Dhuban , et al., ““Coexpression of TIGIT and FCRL3 identifies Helios+ human memory regulatory T cells” The Journal of Immunology, 194(8):3687-3696 (2015)”.
[cited by applicant]
Blanchfield , et al., ““A GMCSF-neuroantigen fusion protein is a potent tolerogen in experimental autoimmune encephalomyelitis (EAE) that is associated with efficient targeting of neuroantigen to APC” Journal of Leukocy…
[cited by applicant]
Boivin , et al., ““Interferon-beta Suppresses Murine Th1 Cell Function in the Absence of Antigen-Presenting Cells” PLoS One, 10:e0124802 (2015)”.
[cited by applicant]
Borden , et al., ““Interferons at age 50: past, current and future impact on biomedicine” Nature Reviews Drug Discovery, 6(12):975-990 (2007) (Abstract only)”.
[cited by applicant]
Brod , et al., ““Modification of acute experimental autoimmune encephalomyelitis in the Lewis rat by oral administration of type 1 interferons” Journal of Interferon & Cytokine Research, 15(2):115-122 (1995) (Abstract o…
[cited by applicant]
Brod , et al., ““Oral administration of human or murine interferon alpha suppresses relapses and modifies adoptive transfer in experimental autoimmune encephalomyelitis” Journal of Neuroimmunology, 58(1):61-69 (1995) (A…
[cited by applicant]
Brod , et al., ““Oral administration of IFN-alpha is superior to subcutaneous administration of IFN-alpha in the suppression of chronic relapsing experimental autoimmune encephalomyelitis” Journal of Autoimmunity, 9(1):…
[cited by applicant]
Brod , et al., ““Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin antigens: IV. Suppression of chronic relapsing disease in the Lewis rat and strain 13 guinea pig” Annals of Neur…
[cited by applicant]
Campbell , et al., ““Myelin basic protein administration in multiple sclerosis” Archives of Neurology, 29(1):10-15 (1973) (Abstract only)”.
[cited by applicant]
Chen , et al., ““IFN-beta induces the proliferation of CD4+CD25+Foxp3+ regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis” Journal of Neuroimmunology, 242(1-2):39-…
[cited by applicant]
Cheng , et al., ““IFN-beta inhibits T cells accumulation in the central nervous system by reducing the expression and activity of chemokines in experimental autoimmune encephalomyelitis” Molecular Immunology, 64(1):152-…
[cited by applicant]
Cobbold , et al., ““Infectious tolerance” Current Opinion in Immunology, 10(5):518-524 (1998) (Abstract only)”.
[cited by applicant]
Cocco , et al., ““Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis” Therapeutics and Clinical Risk Management, 11:759-766 (2015)”.
[cited by applicant]
Comabella, et al., ““Immunopathogenesis of multiple sclerosis” Clinical Immunology, 142(1):2-8 (2012) (Abstract only)”.
[cited by applicant]
Dasch , et al., ““Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification” The Journal of Immunology, 142:1536-1541 (1989…
[cited by applicant]
De Andres , et al., ““Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis” Journal of Neuroimmunology, 182(1-2):204-2…
[cited by applicant]
Dikopoulos , et al., ““Type I IFN Negatively Regulates CD8+ T Cell Responses through IL-10-Producing CD4+ T Regulatory 1 Cells” The Journal of Immunology, 174:99-109 (2005)”.
[cited by applicant]
Elliott , et al., ““Treatment of Experimental Encephalomyelitis with a Novel Chimeric Fusion Protein of Myelin Basic Protein and Proteolipid Protein” The Journal of Clinical Investigation, 98(7):1602-1612 (1996)”.
[cited by applicant]
Faria , et al., ““Oral tolerance: Therapeutic implications for autoimmune diseases” Clinical & Developmental Immunology, 13(2-4):143-157 (2006)”.
[cited by applicant]
Fitzgerald , et al., ““Independent and interdependent immunoregulatory effects of IL-27, IFN-beta, and IL-10 in the suppression of human Th17 cells and murine experimental autoimmune encephalomyelitis” Journal of Immuno…
[cited by applicant]
Floris , et al., ““Interferon-beta directly influences monocyte infiltration into the central nervous system” Journal of Neuroimmunology, 127(1-2):69-79 (2002) (Abstract only)”.
[cited by applicant]
Fontoura , et al., ““Antigen-Specific Therapies in Multiple Sclerosis: Going Beyond Proteins and Peptides” International Reviews of Immunology, 24:415-446 (2005)”.
[cited by applicant]
Freedman , et al., ““A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS” Neurology, 77:1551-1560 (2011)”.
[cited by applicant]
Galligan , et al., ““Interferon-beta is a key regulator of proinflammatory events in experimental autoimmune encephalomyelitis” Multiple Sclerosis, 16(12):1458-1473 (2010)”.
[cited by applicant]
Getts , et al., ““Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis” Nature Biotechnology, 30(12):1217-1224 (2012)”.
[cited by applicant]
Getts , et al., ““Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells” Journal of Immunology, 187(5):2405-2417 (201…
[cited by applicant]
Ghosh , et al., ““Depletion of CD4+ CD25+ regulatory T cells confers susceptibility to experimental autoimmune encephalomyelitis (EAE) in GM-CSF-deficient Csf2-/- mice” Journal of Leukocyte Biology, 100:747-760 (2016)”.
[cited by applicant]
Hawiger , et al., ““Immunological Unresponsiveness Characterized by Increased Expression of CD5 on Peripheral T Cells Induced by Dendritic Cells In Vivo” Immunity, 20:695-705 (2004)”.
[cited by applicant]
Hertz , et al., ““Effect of rat and beta-human interferons on hyperacute experimental allergic encephalomyelitis in rats” Agents and Actions, 16(5):397-403 (1985)”.
[cited by applicant]
Higgins , et al., ““Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments” Journal of Immunology, 140(2):440-445 (1988) (Abstract only)”.
[cited by applicant]
Hou , et al., ““Interferon beta-secreting mesenchymal stem cells combined with minocycline attenuate experimental autoimmune encephalomyelitis” Journal of Neuroimmunology, 274(1-2):20-27 (2014) (Abstract only)”.
[cited by applicant]
Inoue , et al., ““Interferon-beta therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome” Science Signaling, 5(225):ra38 (2012)”.
[cited by applicant]
Inoue , et al., ““The role of interferon-beta in the treatment of multiple sclerosis and experimental autoimmune encephalomyelitis—in the perspective of inflammasomes” Immunology, 139:11-18 (2013)”.
[cited by applicant]
Islam , et al., ““GM-CSF-neuroantigen fusion proteins reverse experimental autoimmune encephalomyelitis and mediate tolerogenic activity in adjuvant-primed environments: association with inflammation-dependent, inhibito…
[cited by applicant]
Javed , et al., ““Exquisite Peptide Specificity of Oral Tolerance in Experimental Autoimmune Encephalomyelitis” The Journal of Immunology, 155: 1599-1605 (1995)”.
[cited by applicant]
Jurynczyk , et al., ““Immune regulation of multiple sclerosis by transdermally applied myelin peptides” Annals of Neurology, 68(5):593-601 (2010) (Abstract only)”.
[cited by applicant]
Kalinke , et al., ““Endogenous, or therapeutically induced, type I interferon responses differentially modulate Th1/Th17-mediated autoimmunity in the CNS” Immunology and Cell Biology, 90:505-509 (2012)”.
[cited by applicant]
Kasper , et al., ““Immunomodulatory activity of interferon-beta” Annals of Clinical and Translational Neurology, 1(8):622-631 (2014)”.
[cited by applicant]
Khorooshi , et al., ““Induction of endogenous Type I interferon within the central nervous system plays a protective role in experimental autoimmune encephalomyelitis” Acta Neuropathologica, 130(1):107-118 (2015)”.
[cited by applicant]
Killestein , et al., ““Determinants of interferon beta efficacy in patients with multiple sclerosis” Nature Reviews Neurology, 7(4):221-228 (2011) (Abstract only)”.
[cited by applicant]
Kool , et al., ““Alum adjuvant: some of the tricks of the oldest adjuvant” Journal of Medical Microbiology, 61:927-934 (2012)”.
[cited by applicant]
Korporal , et al., ““Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells” Archives of Neurology, 65(11):1434-143…
[cited by applicant]
Lacal , et al., ““Monoclonal Antibody Y13-259 Recognizes an Epitope of the p21 ras Molecule Not Directly Involved in the GTP-Binding Activity of the Protein” Molecular and Cellular Biology, 6(4):1002-1009 (1986)”.
[cited by applicant]
Lee , et al., ““Type I Interferons Maintain Foxp3 Expression and T-Regulatory Cell Functions Under Inflammatory Conditions in Mice” Gastroenterology, 143(1):145-154 (2012)”.
[cited by applicant]
Levings , et al., ““IFN-alpha and IL-10 Induce the Differentiation of Human Type 1 T Regulatory Cells” The Journal of Immunology, 166:5530-5539 (2001)”.
[cited by applicant]
Limmroth , et al., “The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dos…
[cited by applicant]
Liu, et al., ““FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS” Nature Medicine, 20:272-282 (2014)”.
[cited by applicant]
Liu , et al., ““Tumor Evasion of the Immune System by Converting CD4+CD25-T Cells into CD4+CD25+ T Regulatory Cells: Role of Tumor-Derived TGF-beta” The Journal of Immunology, 178:2883-2892 (2007)”.
[cited by applicant]
Loo , et al., ““High dose antigen treatment with a peptide epitope of myelin basic protein modulates T cells in multiple sclerosis patients” Cellular Immunology, 280(1):10-15 (2012) (Abstract only)”.
[cited by applicant]
Lund , et al., ““Coordination of Early Protective Immunity to Viral Infection by Regulatory T Cells” Science, 320(5880):1220-1224 (2008)”.
[cited by applicant]
Lutterotti , et al., ““Antigen-Specific Tolerance by Autologous Myelin Peptide-Coupled Cells: A Phase 1 Trial in Multiple Sclerosis” Science Translational Medicine, 5:188ra175 (2013)”.
[cited by applicant]
Mannie , et al., ““A Fusion Protein Consisting of IL-16 and the Encephalitogenic Peptide of Myelin Basic Protein Constitutes an Antigen-Specific Tolerogenic Vaccine That Inhibits Experimental Autoimmune Encephalomyeliti…
[cited by applicant]
Mannie , et al., ““Class II MHC/peptide complexes on T cell antigen-presenting cells: agonistic antigen recognition inhibits subsequent antigen presentation” Cellular Immunology, 186(2):111-120 (1998) (Abstract only)”.
[cited by applicant]
Mannie , et al., ““Cytokine-neuroantigen fusion proteins as a new class of tolerogenic, therapeutic vaccines for treatment of inflammatory demyelinating disease in rodent models of multiple sclerosis” Frontiers in Immun…
[cited by applicant]
Mannie , et al., ““Cytokine-neuroantigen fusion proteins: new tools for modulation of myelin basic protein (MBP)-specific T cell responses in experimental autoimmune encephalomyelitis” The Journal of Immunological Metho…
[cited by applicant]
Mannie , et al., ““Experimental Autoimmune Encephalomyelitis in Lewis rats: IFN-beta Acts As a Tolerogenic Adjuvant for Induction of Neuroantigen-Dependent Tolerance” The Journal of Immunology, 182:5331-5341 (2009)”.
[cited by applicant]
Mannie , et al., ““IL-2/Neuroantigen Fusion Proteins as Antigen-Specific Tolerogens in Experimental Autoimmune Encephalomyelitis (EAE): Correlation of T Cell-Mediated Antigen Presentation and Tolerance Induction” The Jo…
[cited by applicant]
Mannie , et al., ““Parallel costimulatory pathways promote myelin basic protein-stimulated proliferation of encephalitogenic rat T cells” Cellular Immunology, 153(2):312-328 (1994) (Abstract only)”.
[cited by applicant]
Mannie , et al., ““Tolerogenic vaccines for Multiple sclerosis” Human Vaccines & Immunotherapeutics, 9(5):1032-1038 (2013)”.
[cited by applicant]
Marta , et al., ““Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology” Proceedings of the National Academy of Sciences USA, 102(39):13992-1399…
[cited by applicant]
Marziniak , et al., ““Current Perspectives on Interferon Beta-1b for the Treatment of Multiple Sclerosis” Advances in Therapy, 31(9):915-931 (2014)”.
[cited by applicant]
Mcfarland , et al., ““Effective Antigen-Specific Immunotherapy in the Marmoset Model of Multiple Sclerosis” The Journal of Immunology, 166:2116-2121 (2001)”.
[cited by applicant]
Mcgraw , et al., ““Interferon Beta and Glatiramer Acetate Therapy” Neurotherapeutics, 10:2-18 (2013)”.
[cited by applicant]
Metidji , et al., ““IFN-alpha/beta Receptor Signaling Promotes Regulatory T Cell Development and Function Under Stress Conditions” The Journal of Immunology, 194(9):4265-4276 (2015)”.
[cited by applicant]
Miller , et al., ““Experimental Autoimmune Encephalomyelitis in the Mouse” Current Protocols in Immunology, 77(1):15.1.1-15.1.18 (2007)”.
[cited by applicant]
Mori , et al., ““The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses” European Journal of Immunology, 42:2709-2719 (2012)”.
[cited by applicant]
Namdar , et al., ““Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study” Journal of…
[cited by applicant]
Nikfar , et al., ““A meta-analysis of the efficacy and tolerability of interferon-beta in multiple sclerosis, overall and by drug and disease type” Clinical Therapeutics, 32(11):1871-1888 (2010) (Abstract only)”.
[cited by applicant]
Nylander , et al., ““Multiple Sclerosis” The Journal of Clinical Investigation, 122(4):1180-1188 (2012)”.
[cited by applicant]
Oleszycka, et al., ““Immunomodulatory properties of the vaccine adjuvant alum” Current Opinion in Immunology, 28:1-5 (2014) (Abstract only)”.
[cited by applicant]
Oliveira , et al., ““Adjuvant facilitates tolerance induction to factor VIII in hemophilic mice through a Foxp3-independent mechanism that relies on IL-10” Blood, 121(19):3936-3945 (2013)”.
[cited by applicant]
Oliver , et al., ““Interferon therapy in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of the comparative trials” Journal of the Neurological Sciences, 302(1-2):96-105 (2011) (Abstract on…
[cited by applicant]
Oliver , et al., ““Rat and Human Myelin Oligodendrocyte Glycoproteins Induce Experimental Autoimmune Encephalomyelitis by Different Mechanisms in C57BL/6 Mice” The Journal of Immunology, 171:462-468 (2003)”.
[cited by applicant]
Olson , et al., ““Interleukin 35: a key mediator of suppression and the propagation of infectious tolerance” Frontiers in Immunology, 4(315):1-12 (2013)”.
[cited by applicant]
Papadopoulou , et al., ““Evolution of MS lesions to black holes under DNA vaccine treatment” Journal of Neurology, 259:1375-1382 (2012)”.
[cited by applicant]
Piconese , et al., ““Divergent effects of type-I interferons on regulatory T cells” Cytokine & Growth Factor Reviews, 26(2):133-141 (2015) (Abstract only)”.
[cited by applicant]
Prinz , et al., ““Distinct and Nonredundant In Vivo Functions of IFNAR on Myeloid Cells Limit Autoimmunity in the Central Nervous System” Immunity, 28:675-686 (2008)”.
[cited by applicant]
Raffin , et al., ““Human Memory Helios2 FOXP3+ Regulatory T Cells (Tregs) Encompass Induced Tregs That Express Aiolos and Respond to IL-1b by Downregulating Their Suppressor Functions” The Journal of Immunology, 191(9):…
[cited by applicant]
Rangachari , et al., ““Using EAE to better understand principles of immune function and autoimmune pathology” Journal of Autoimmunity, 45:31-39 (2013)”.
[cited by applicant]
Reed, et al., ““New horizons in adjuvants for vaccine development” Trends in Immunology, 30(1):23-32 (2009) (Abstract only)”.
[cited by applicant]
Rudick , et al., ““Beta-interferon for multiple sclerosis” Experimental Cell Research, 317(9):1301-1311 (2011) (Abstract only)”.
[cited by applicant]
Sabatos-Peyton , et al., ““Antigen-specific immunotherapy of autoimmune and allergic diseases” Current Opinion in Immunology, 22:609-615 (2010)”.
[cited by applicant]
Sanford , et al., ““Subcutaneous recombinant interferon-beta-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis” Drugs, 71(14):1865-1891 (2011) (Abstract only)”.
[cited by applicant]
Setiady , et al., ““In vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcgammaRIII+ phagocytes” European Journal of Immunology, 40(3):780-786 (2010)”.
[cited by applicant]
Shevach , et al., ““tTregs, pTregs, and iTregs: Similarities and Differences” Immunological Reviews, 259(1):88-102 (2014)”.
[cited by applicant]
Simmons , et al., ““Modeling the Heterogeneity of Multiple Sclerosis in Animals” Trends in Immunology, 34 (8):410-422 (2013)”.
[cited by applicant]
Stassen , et al., ““Human CD(4+)CD(25+) regulatory T cells and infectious tolerance” Transplantation, 77(1):S23-S25 (2004)”.
[cited by applicant]
Stern , et al., ““Promoting tolerance to proteolipid protein-induced experimental autoimmune encephalomyelitis through targeting dendritic cells” Proceedings of the National Academy of Sciences USA, 107(40):17280-17285 …
[cited by applicant]
Stewart , et al., ““Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation” The Journal of Clinical Investigation, 123(11):4859-4874 (2013)”.
[cited by applicant]
Takatori , et al., ““Helios Enhances Treg Cell Function in Cooperation With FoxP3” Arthritis & Rheumatology, 67(6):1491-1502 (2015)”.
[cited by applicant]
Tuohy , et al., ““Modulation of the IL-10/IL-12 cytokine circuit by interferon-beta inhibits the development of epitope spreading and disease progression in murine autoimmune encephalomyelitis” Journal of Neuroimmunolog…
[cited by applicant]
Vandenbark , et al., ““Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis” Journal of Neuroimmunology, 215(1-2):125-128 (2009) (Abst…
[cited by applicant]
Vriesendorp , et al., ““Oral administration of type I interferon modulates the course of experimental allergic neuritis” Autoimmunity, 24(3):157-165 (1996) (Abstract only)”.
[cited by applicant]
Walczak , et al., ““Transdermal Application of Myelin Peptides in Multiple Sclerosis Treatment” JAMA Neurology, 70(9):1105-1109 (2013)”.
[cited by applicant]
Waldmann , et al., ““Infectious tolerance and the long-term acceptance of transplanted tissue” Immunological Reviews, 212:301-313 (2006) (Abstract only)”.
[cited by applicant]
Wang , et al., ““IFN-Beta Facilitates Neuroantigen-Dependent Induction of CD25+ FOXP3+ Regulatory T Cells that Suppress Experimental Autoimmune Encephalomyelitis” The Journal of Immunology, 197:2992-3007 (2016)”.
[cited by applicant]
Wang , et al., ““An Essential Role of the Transcription Factor GATA-3 for the Function of Regulatory T Cells” Immunity, 35(3):337-348 (2011)”.
[cited by applicant]
Wang , et al., ““An Intrinsic Mechanism Predisposes Foxp3-Expressing Regulatory T Cells to Th2 Conversion In Vivo” The Journal of Immunology, 185(10):5983-5992 (2010)”.
[cited by applicant]
Weiner , et al., ““Oral Tolerance” Immunological Reviews, 206:232-259 (2005)”.
[cited by applicant]
Wigren , et al., ““Atheroprotective Effects of Alum Are Associated With Capture of Oxidized LDL Antigens and Activation of Regulatory T Cells” Circulation Research, 104(12):e62-70 (2009)”.
[cited by applicant]
Yasuda , et al., ““Interferon beta modulates experimental autoimmune encephalomyelitis by altering the pattern of cytokine secretion” Immunological Investigations, 28(2-3):115-126 (1999) (Abstract only)”.
[cited by applicant]
Yu, et al., ““Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis” Journal of Neuroimmunology, 64(1):91-100 (1996) (Abstract only)”.
[cited by applicant]
Zhornitsky , et al., ““Prolactin in combination with interferon-beta reduces disease severity in an animal model of multiple sclerosis” Journal of Neuroinflammation, 12(55):1-7 (2015)”.
[cited by applicant]
Ziegler-Heitbrock , et al., ““IFN-alpha Induces the Human IL-10 Gene by Recruiting Both IFN Regulatory Factor 1 and Stat3” The Journal of Immunology, 171:285-290 (2003)”.
[cited by applicant]
Zou , et al., ““Overexpression of human transforming growth factor-beta1 using a recombinant CHO cell expression system” Protein Expression and Purification, 37(2):265-272 (2004) (Abstract only)”.
[cited by applicant]
Examination Report corresponding to European Application No. 16852494.0 dated Dec. 4, 2023.
[cited by applicant]
Moorman et al., “A GMCSF-Neuroantigen Tolerogenic Vaccine Elicits Systemic Lymphocytosis of CD4+ CD25high FOXP3+ Regulatory T Cells in Myelin-Specific TCR Transgenic Mice Contigent Upon Low-Efficiency T Cell Antigen Rec…
[cited by applicant]
Kenney et al., Protective Immunity Using Recombinant Human IL-12 and Alum as Adjuvants in a Primate Model of Cutaneous Leishmaniasis, J Immunol, 1999, 163(8), pp. 4481-4488.
[cited by applicant]
Faul et al.,. Intereron-β expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity, Virology, Dec. 20, 2008, 382(2), pp. 226-238.
[cited by applicant]
Casas et al., “Redosing with Intralymphatic GAD-Alum in the Treatment of Type 1 Diabetes: The Diagnode-B Pilot Trial,” Int. J. Mol. Sci., 2025, 26, 374, 16 pages.
[cited by applicant]
Bagavant et al. “Alum, an Aluminum Based Adjuvant, Induces Sjogren's Syndrome-like Disorder in Mice,” Clin Exp Rheumatol, 2014; 32(2), pp. 251-255.
[cited by applicant]
Wallberg et al., “Vaccination with myelin oligodendrocyte glycoprotein adsorbed to alum effectively protects DBA/1 mice from experimental autoimmune encephalomyelitis,” Eur. J. Immunol., 2003, 33, pp. 1539-1547.
[cited by applicant]